Go Pro
NYSE:BIO.B

Bio-Rad Laboratories (BIO.B) Stock Price, News & Analysis

Bio-Rad Laboratories logo
$309.37 0.00 (0.00%)
As of 07/29/2026

About Bio-Rad Laboratories Stock (NYSE:BIO.B)

Advanced

Key Stats

Today's Range
$309.37
$309.37
50-Day Range
$267.43
$309.37
52-Week Range
$244.54
$321.12
Volume
8 shs
Average Volume
57 shs
Market Capitalization
$8.28 billion
P/E Ratio
50.97
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Bio-Rad Laboratories, Inc. is a global provider of innovative products and systems that serve the life science research and clinical diagnostics markets. The company operates through two primary segments: Life Science, which delivers instruments, consumables and software for research applications, and Clinical Diagnostics, which offers quality control materials and reagent systems for blood typing, immunology and molecular testing. Bio-Rad’s product portfolio supports a wide range of applications, including protein analysis, gene expression, cell biology and digital PCR.

In the Life Science segment, Bio-Rad develops and markets technologies such as electrophoresis and imaging systems, chromatography instruments, laboratory consumables and software platforms that streamline experimental workflows. Researchers in academic institutions, pharmaceutical and biotechnology companies rely on these tools for applications in proteomics, genomics, cell biology and biopharmaceutical process development. Bio-Rad’s innovations, including its digital droplet PCR technology, have been widely adopted for applications that require high sensitivity, precision and reproducibility.

The Clinical Diagnostics segment provides products used by hospitals, reference laboratories and transfusion centers around the world. Offerings include quality control materials, blood grouping and antibody detection reagents, molecular diagnostic assays and automated systems designed to improve the accuracy and efficiency of patient testing. Bio-Rad’s diagnostic solutions support applications such as infectious disease screening, diabetes monitoring and prenatal testing, and are backed by technical service and training to ensure compliance with regulatory standards.

Founded in 1952 and headquartered in Hercules, California, Bio-Rad maintains a broad international footprint with manufacturing sites and sales offices across North America, Europe, Asia-Pacific and Latin America. Over its history, the company has grown through both internal research and development and strategic acquisitions, strengthening its position in critical markets. Bio-Rad continues to invest in product innovation and global expansion to support customers in advancing scientific discovery and delivering reliable clinical results.

AI Generated. May Contain Errors.

Receive BIO.B Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Rad Laboratories and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BIO.B Stock News Headlines

Bio-Rad Laboratories, Inc. Class B
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to move out of overpriced AI stocks before the tech trade breaks down and into lesser-known names with real potential to challenge the Mag 7. One pick he calls 'an upgrade to Tesla stock' is a little-known company that just inked a partnership with Nvidia, positioning it ahead of Tesla in the autonomous vehicle race.tc pixel
See More Headlines

BIO.B Stock Analysis - Frequently Asked Questions

Bio-Rad Laboratories' stock was trading at $310.70 on January 1st, 2026. Since then, BIO.B stock has decreased by 0.4% and is now trading at $309.3740.

Bio-Rad Laboratories, Inc. (NYSE:BIO.B) released its earnings results on Thursday, April, 30th. The company reported $1.89 EPS for the quarter. Bio-Rad Laboratories had a net margin of 6.52% and a trailing twelve-month return on equity of 3.56%.

Bio-Rad Laboratories subsidiaries include these companies: Celsee, Raindance Technologies Limited, GnuBIO Inc., Bio-Rad AbD Serotec GmbH, QuantaLife, DiaMed Holding AG, Blackhawk Biosystems, and more.

Shares of BIO.B stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
4/30/2026
Today
7/31/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Measuring And Control Equipment
Current Symbol
NYSE:BIO.B
CIK
12208
Employees
8,200
Year Founded
1952

Profitability

EPS (Trailing Twelve Months)
$6.07
Trailing P/E Ratio
50.97
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$759.90 million
Net Margins
6.52%
Pretax Margin
8.58%
Return on Equity
3.56%
Return on Assets
2.49%

Debt

Debt-to-Equity Ratio
0.12
Current Ratio
3.21
Quick Ratio
2.37

Sales & Book Value

Annual Sales
$2.58 billion
Price / Sales
3.20
Cash Flow
$10.02 per share
Price / Cash Flow
30.87
Book Value
$276.16 per share
Price / Book
1.12

Miscellaneous

Outstanding Shares
26,760,000
Free Float
19,167,000
Market Cap
$8.28 billion
Optionable
Not Optionable
Beta
0.94

Social Links

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

This page (NYSE:BIO.B) was last updated on 7/31/2026 by MarketBeat.com Staff.
From Our Partners